83 84

Cited 2 times in

Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea

DC FieldValueLanguage
dc.contributor.author김현창-
dc.contributor.author최한솔-
dc.date.accessioned2018-08-28T17:24:28Z-
dc.date.available2018-08-28T17:24:28Z-
dc.date.issued2018-
dc.identifier.issn1738-5520-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/162568-
dc.description.abstractBACKGROUND AND OBJECTIVES: To compare cardiovascular disease (CVD) risk associated with 5 different dipeptidyl peptidase-4 inhibitors (DPP-4is) in people with type 2 diabetes. METHODS: We identified 534,327 people who were newly prescribed sitagliptin (n=167,157), vildagliptin (n=67,412), saxagliptin (n=29,479), linagliptin (n=220,672), or gemigliptin (n=49,607) between January 2013 and June 2015 using the claims database of the Korean National Health Insurance System. A Cox proportional hazards model was used to estimate hazard ratios (HRs) for major CVD events (myocardial infarction, stroke, or death) among users of different DPP-4is. The model was adjusted for sex, age, duration of DPP-4i use, use of other glucose-lowering drugs, use of antiplatelet agents, hypertension, dyslipidemia, atrial fibrillation, chronic kidney disease, microvascular complications of diabetes, Charlson comorbidity index, and the calendar index year as potential confounders. RESULTS: Compared to sitagliptin users, the fully adjusted HRs for CVD events were 0.97 (95% confidence interval [CI], 0.94-1.01; p=0.163) for vildagliptin, 0.76 (95% CI, 0.71-0.81; p<0.001) for saxagliptin, 0.95 (95% CI, 0.92-0.98; p<0.001) for linagliptin, and 0.84 (95% CI, 0.80-0.88; p<0.001) for gemigliptin. CONCLUSIONS: Compared to sitagliptin therapy, saxagliptin, linagliptin, and gemigliptin therapies were all associated with a lower risk of cardiovascular events.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish, Korean-
dc.publisherKorean Society of Circulation-
dc.relation.isPartOfKOREAN CIRCULATION JOURNAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleComparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Preventive Medicine-
dc.contributor.googleauthorKyoung Hwa Ha-
dc.contributor.googleauthorBongseong Kim-
dc.contributor.googleauthorHae Sol Shin-
dc.contributor.googleauthorJinhee Lee-
dc.contributor.googleauthorHansol Choi-
dc.contributor.googleauthorHyeon Chang Kim-
dc.contributor.googleauthorDae Jung Kim-
dc.identifier.doi10.4070/kcj.2017.0324-
dc.contributor.localIdA01142-
dc.contributor.localIdA05433-
dc.relation.journalcodeJ01952-
dc.identifier.eissn1738-5555-
dc.identifier.pmid29671284-
dc.subject.keywordCardiovascular diseases-
dc.subject.keywordDipeptidyl-peptidase IV inhibitors-
dc.subject.keywordType 2 diabetes mellitus-
dc.contributor.alternativeNameKim, Hyeon Chang-
dc.contributor.alternativeNameChoi, Han Sol-
dc.contributor.affiliatedAuthorKim, Hyeon Chang-
dc.contributor.affiliatedAuthorChoi, Han Sol-
dc.citation.volume48-
dc.citation.number5-
dc.citation.startPage395-
dc.citation.endPage405-
dc.identifier.bibliographicCitationKOREAN CIRCULATION JOURNAL, Vol.48(5) : 395-405, 2018-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Preventive Medicine and Public Health (예방의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.